MITA Says JAMA Editorial Supporting Medicare Coverage of Low-Dose Lung CT for High-Risk Beneficiaries Relies on Sound Data


Washington, D.C. – The Medical Imaging & Technology Alliance (MITA) today said it supports the editorial written by Douglas E. Wood, MD, FRCSEd in the October issue of the Journal of the American Medical Association, which concludes that the Centers for Medicare & Medicaid Services (CMS) should cover low-dose computed tomography (LDCT) for beneficiaries at high risk for lung cancer.

“We agree with Dr. Wood’s assessment that there is an abundance of evidence that demonstrates LDCT scans could save the lives of Medicare beneficiaries who are at high-risk for lung cancer,” said Gail Rodriguez, executive director of MITA. “Given recent research that confirms it can be done in a cost effective manner, we encourage CMS to provide this population with access to the life-saving benefits of early detection.”

In his editorial, “The Importance of Lung Cancer Screening with Low-Dose Computed Tomography for Medicare Beneficiaries,” Dr. Wood states that LDCT scans lower the lung cancer mortality rate in at-risk patients. Dr. Wood also argues that private insurers must cover certain preventive services under the Affordable Care Act, but CMS has no equivalent for Medicare beneficiaries. He explains that without Medicare coverage, patients screened through private insurers abruptly lose this ability at age 64, when the risk of developing lung cancer is heightened.

In line with Dr. Wood’s proposal, the American Medical Association recommends requiring coverage of LDCT scans for patients at high risk for lung cancer by Medicare, Medicaid and private insurance.


The Medical Imaging & Technology Alliance (MITA), a division of NEMA, is the collective voice of medical imaging equipment, radiation therapy and radiopharmaceutical manufacturers, innovators and product developers. It represents companies whose sales comprise more than 90 percent of the global market for medical imaging and radiation therapy technologies. For more information, visit Follow MITA on Twitter @MITAToday.